Ultime notizie per NexImmune (OTC:NEXI) Azioni

NexImmune

NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

NexImmune Inc

Nexi SpA

NEXIEN BIOPHARMA INC by Nexien BioPharma, Inc.

Nexien BioPharma Inc

NEXIS INTL INDUS INC by Nexis International Industries, Inc.

Nexis International Industries Inc

NEXITY FINANCIAL CORP by Nexity Financial Corp.

Nexity Financial Corp

Nexity SA

WIIM

CVCO

Cavo Industries shares are trading higher after the company reported better-than-expected Q2 financial results and announced a $100 million stock repurchase program.

<a href="https://www.bloomberg.com/news/articles/2024-11-01/meta-loses-bid-to-appeal-uk-class-action-over-user-data">https://www.bloomberg.com/news/articles/2024-11-01/meta-loses-bid-to-appeal-uk-class-action-over-user-data</a>
<a href="https://www.bloomberg.com/quote/FB:US">Meta Platforms Inc.</a> failed in a bid to challenge a class action suit in the UK that alleged Facebook abused its dominant position and exploited its users personal data.
The <a href="https://www.bloomberg.com/quote/6152Z:LN">UK</a>'s Court of Appeal refused to permit Meta and Facebook's UK unit to challenge a competition appeals court which had greenlit a revised version of the lawsuit. The court rejected Meta's appeal at a hearing on October 7, but only published the detailed ruling on Friday.

News

Legal

'Meta Loses Bid To Appeal UK Class Action Over User Data' - Bloomberg News

Guggenheim analyst Shahriar Pourreza maintains Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) with a Buy and raises the price target from $145 to $165.

Price Target

Analyst Ratings

Guggenheim Maintains Buy on Entergy, Raises Price Target to $165

PATK

Patrick Industries shares are trading lower after the company reported worse-than-expected Q3 financial results. Also, Raymond James lowered its price target on the stock from $160 to $138.

Guggenheim analyst Robert Drbul maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Buy and raises the price target from $80 to $100.

Guggenheim Maintains Buy on Kontoor Brands, Raises Price Target to $100

VRRM

Verra Mobility shares are trading lower after the company reported worse-than-expected Q3 revenue results and issued FY24 revenue guidance below estimates. Also, Barid and Deutsche Bank lowered their respective price targets on the stock.

ONTO

Onto Innovation shares are trading lower after Needham cut its price target on the stock from $245 to $230.

Microsoft Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) decision to shut down Arkane Austin, the studio behind acclaimed titles like Redfall and Prey, has faced blunt criticism from industry veteran and Arkane founder Raphaël Colantonio. 
Colantonio, now leading WolfEye Studios, described the decision <a href="https://www.pcgamer.com/games/microsoft-closing-arkane-austin-was-a-dumb-move-says-founder-and-former-president/">to</a> PC Gamer as "stupid" and "not a good decision."
<h3 class="wp-block-heading">A &#8216;Special Group&#8217; Cut In A Corporate Reshuffle</h3>
Reflecting on the closure, Colantonio said: "I think if you look a little bit, it&#8217;s obvious that Arkane Austin was a very special group of people that have made some cool things and that could pull it off again." 
See Also: <a href="https://www.benzinga.com/general/gaming/24/06/39417676/microsoft-issues-redfall-hero-pass-dlc-refunds-after-arkane-austin-closure">Microsoft Issues Redfall Hero Pass DLC Refunds After Arkane Austin Closure</a>
He added: "I think it was a decision that just came down to, &#8216;We need to cut something.&#8217; Was it to please the investors, the stock market? They&#8217;re playing a different game."
The closure of Arkane Austin, alongside studios like Tango Gameworks and Alpha Dog Games, formed part of a broader reorganization within Microsoft, which had announced plans to reduce its gaming division workforce by 1,900 employees. 
In a memo, Xbox Game Studios head Matt Booty cited "reprioritization of titles and resources" as the driving force behind the cuts. 
While Microsoft&#8217;s CEO Satya Nadella received a notable pay raise to $30 million last year, the company continues to grapple with evolving industry demands and cost pressures.
<h3 class="wp-block-heading">Irreplaceable Talent And The Challenge Of Rebuilding</h3>
Colantonio doubted whether the unique chemistry at Arkane Austin could ever be replicated. He pointed to key team members like Harvey Smith and Ricardo Bare, whose collaboration played a huge role in the studio&#8217;s achievements. 
"When you have that magic of Harvey and Ricardo etc. that all come together, it&#8217;s a specific moment in time and space that just worked out this way, that took forever to reach,&#8221; he said. &#8220;Those people together can really make magic."
"It's not like, &#8216;Doesn&#8217;t matter, we&#8217;ll just rehire.&#8217; No, try it. That's what big groups do all the time. They try to just hire massively and overpay people to create those magic groups. It doesn't work like this. So to me, that was stupid. But what do I know?"
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/06/39534876/bethesda-game-studios-montreal-announces-unionization-plans">Bethesda Game Studios Montreal Announces Unionization Plans</a></li>
</ul>
Image credits: Shutterstock.

Gaming

General

MSFT

Microsoft's Decision To Shut Down Arkane Austin Called 'Stupid' By Studio Founder

MDGL

Madrigal Pharmaceuticals shares are trading higher after UBS maintained a Buy rating on the stock and raised its price target from $411 to $441.

MDU Resources shares are trading lower. Everus Construction Group completed its spinoff from the company.

Benchmark analyst Josh Sullivan maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Buy and raises the price target from $150 to $300.

FTAI

Benchmark Maintains Buy on FTAI Aviation, Raises Price Target to $300

ARES

Ares Management shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Bio-Rad Laboratories shares are trading higher after Citigroup maintained a Buy rating on the stock and raised its price target from $400 to $450.

Church & Dwight shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 net sales guidance.

<ul>
<li>IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person's underlying mental health condition</li>
<li>Registry revealed fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%)</li>
<li>Teva continues to further innovations in mental health and progress real-world data to improve treatment optimization</li>
</ul>
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO&#xAE; XR&#xAE; (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.

Biotech

TEVA

Teva Presents New Tardive Dyskinesia Data At Psych Congress 2024 From The IMPACT-TD Registry, Revealing Differences In Patient Experience Based On Underlying Psychiatric Condition; Registry Revealed Fewer Patients With Psychotic Disorders (36%) Received TD Diagnoses Compared To Those With Mood Disorders (50%)

MBLY

Mobileye Global shares are trading higher after Baird and TD Cowen raised their respective price targets on the stock.

Investment firm 21Shares submitted a request to the U.S. Securities and Exchange Commission (SEC) for approval to launch a spot XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41653546/blackrocks-bitcoin-etf-crosses-1-million-btc-in-assets-under-management">exchange-traded fund (ETF)</a>.
What Happened: 21Shares <a href="https://www.sec.gov/Archives/edgar/data/2028835/000121390024093305/ea0219336-01.htm">filed</a> an S-1 registration statement with the SEC on Friday proposing a fund, named the 21Shares Core XRP Trust to be listed on the Cboe BZX Exchange. Coinbase Custody Trust Company is expected to serve as the fund&#8217;s custodian.
This move is part of 21Shares&#8217; ongoing efforts to expand U.S. investor access to the cryptocurrency asset class. The firm joins a growing list of companies competing for different crypto ETFs, following the SEC&#8217;s initial approval of crypto ETFs earlier this year.
The Block <a href="https://www.theblock.co/post/324186/21shares-looks-to-secure-sec-approval-for-xrp-etf-amid-growing-interest-in-other-crypto-funds?utm_source=rss&amp;utm_medium=rss">reported</a> that Canary Capital and Bitwise are among the other firms applying for a spot XRP ETF despite possible challenges.
The SEC has previously been <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41157465/gary-genslers-sec-appeals-2023-ruling-against-ripple-labs-xrp-tanks-10-just-prolongs-compl">involved in a legal dispute with Ripple</a>, accusing the company of raising $1.3 billion through the sale of XRP, which it considers an unregistered security. The case between Ripple and the SEC is still ongoing.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41653546/blackrocks-bitcoin-etf-crosses-1-million-btc-in-assets-under-management">BlackRock&#8217;s Bitcoin ETF Crosses 1 Million BTC In Assets Under Management</a>
Why It Matters: The recent move by 21Shares to seek approval for an XRP ETF indicates a growing trend among investment firms to broaden investor access to the cryptocurrency market through ETFs.
This development comes in the wake of increased interest in cryptocurrency ETFs. In July 2024, Cboe Global Markets Inc. had submitted a request to the SEC to list Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) spot exchange-traded funds applied by VanEck and 21Shares. If approved, these would be the <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39679535/solana-jumps-5-5-as-cboe-files-application-with-sec-to-list-vaneck-21shares-spot-etfs">first ETF products linked to Solana.</a>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41584575/bitcoin-etfs-vs-ethereum-etfs-why-does-eth-keep-underperforming">Bitcoin ETFs Vs Ethereum ETFs: Why Does ETH Keep Underperforming?</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

$XRP

XRP ETF Coming Soon? 21Shares Files For One Despite Ripple's Legal Battles

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple" target="_blank" rel="noreferrer noopener">EXCLUSIVE – Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week of Nov. 1:
Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) saw increased interest from investors during the week, which comes ahead of several potential catalysts. The life sciences and diagnostics company is set to report fourth-quarter financial results on Nov. 25 and host an analyst day on Dec. 17. Recent <a href="https://www.benzinga.com/quote/A/analyst-ratings">analyst activity</a> on the stock saw Barclays maintain an Underweight rating while raising the price target from $135 to $145. Evercore ISI maintains an In-Line rating while raising the price target from $135 to $145. The stock was up over 3% in the last five trading days as shown on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1">Benzinga Pro chart </a>below. It remains down around 2% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1001" height="462" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227.png" alt="" class="wp-image-626124" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227-300x138.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227-768x354.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) saw increased interest from investors ahead of third-quarter financial results, which are set for Nov. 7. Analysts expect the company to report earnings per share of 39 cents and revenue of $619.8 million, compared to earnings of 33 cents per share and revenue of $493.3 million in last year's third quarter. Trade Desk has beaten earnings per share estimates in seven of the last eight quarters and beaten revenue estimates from analysts in more than 10 straight quarters.
Wedbush analyst Daniel Ives <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41144914/meta-trade-desk-amazon-digital-ad-titans-set-for-strong-2025-growth-tech-analyst-sa">recently highlighted </a>the growth potential for Trade Desk in the third quarter.
&#8220;Our survey showed accelerating growth for TTD in 3Q versus 2Q,&#8221; Ives said.
Trade Desk's <a href="https://www.benzinga.com/news/earnings/24/08/40267737/the-trade-desk-stock-climbs-after-better-than-expected-q2-results">second-quarter results</a> saw a customer retention rate of over 95%, continuing a 10-year streak. With potential strong growth and AI initiatives being integrated, the stock could generate some buzz with its third-quarter results.
The stock was down slightly over the last five days, but is up around 70% year-to-date.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228.png" alt="" class="wp-image-626125" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228-768x384.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Schwab US Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) made the list for the first time. The Stock Whisper Index typically highlights only stocks and leaves the ETFs out. But each week, ETFs like the SPY, QQQ and sometimes other well-known ETFs see rising interest based on volatility. Schwab tracks the Dow Jones U.S. Dividend 100 Index. It offers investors exposure to some of the largest U.S. companies that pay dividends and have a strong track record of paying out dividends. Top holdings in the ETF include Bristol Myers Squibb, Blackrock, Cisco Systems, Home Depot and Chevron.
With rising global tensions, macroeconomic uncertainties and the 2024 presidential election leaving some investors on edge, the ETF could be seeing increased interest thanks to its dividend income and positions in blue chip companies.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="512" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229.png" alt="" class="wp-image-626126" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229-768x394.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Reinsurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>): The life and health reinsurance company saw increased interest over the week likely due to quarterly financial <a href="https://investor.rgare.com/news-releases/news-release-details/reinsurance-group-america-reports-record-third-quarter-results">results</a>. The company reported third-quarter earnings per share of $6.13 and revenue of $5.65 billion, beating Street consensus estimates according to Benzinga Pro. Reinsurance Group's third quarter had record financial results. The strong quarter could put the stock on investors radar for future growth opportunities.
Shares of the reinsurance company were up around 2% for the last five days and are up over 30% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230.png" alt="" class="wp-image-626127" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230-768x387.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) is scheduled to report third-quarter financial results on Nov. 6. The company is behind the PreTRM test for pregnancy preterm testing. An investor presentation highlighted the company's future product pipeline to include a predictive analytics product and a time-to-birth test. Shares of the pregnancy diagnostics company were up 16% over the last five trading days.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231.png" alt="" class="wp-image-626128" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231-768x388.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 4</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/10/41296909/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 11</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/10/41405659/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 18</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/10/41549488/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">October 25</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a" target="_blank" rel="noreferrer noopener">Interest Rates In Free-Fall: What It Means For Mortgages, Credit Cards And Your Wallet</a></li>
</ul>

Exclusives

Trading Ideas

SCHD

SERA

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

MSTR

MicroStrategy shares are trading lower. The company may be moving on continued weakness after reporting worse-than-expected Q3 financial results on Wednesday.

Zions Bancorporation, N.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) announced today that its board of directors ("board") declared a regular quarterly dividend of $0.43 per common share, payable November 21, 2024, to shareholders of record at the close of business on November 14, 2024.

Dividends

ZION

Zions Bancorporation Increases Quarterly Dividend From $0.41 To $0.43 Per Share

Neximmune Inc (NEXI) stock has fallen -43.40% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives NEXI stock a score of  24 out of a possible 100. That rank is mainly influenced by a long-term technical score of 32. NEXI's rank also includes a short-term technical score of 40.  NEXI has an Overal

Is Neximmune Inc (NEXI) Stock a Bad Value?

XXII, GRIN and XTIA are among mid-day movers

NexImmune (NEXI) has issued an update. NexImmune, Inc. is undergoing a transition in its financial leadership, with Timothy Stover stepping down as...

NexImmune Announces Leadership Shift in Financial Management

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NexImmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/nexi-stock-quote/">NEXI</a>) just reported results for the fourth quarter of 2023.<ul><li>NexImmune reported earnings per share of -$4.99.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/nexi-stock-earnings-neximmune-for-q4-of-2023/">NEXI Stock Earnings: NexImmune Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NEXI Stock Earnings: NexImmune Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NexImmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/nexi-stock-quote/">NEXI</a>) just reported results for the first quarter of 2024.<ul><li>NexImmune reported earnings per share of -$2.46.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/nexi-stock-earnings-neximmune-for-q1-of-2024/">NEXI Stock Earnings: NexImmune Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NEXI Stock Earnings: NexImmune Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Embattled biotechnology firm NexImmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/nexi-stock-quote/">NEXI</a>) is seeing shares skyrocket on Thursday, possibly due to anticipation around a lingering business matter. Due to severe financial struggles, management has sought to dissolve the enterprise. However, it has consistently failed to meet quorum. Still, the dramatic rise of NEXI stock today suggests that a resolution has passed or has a strong chance of doing so.



In a <a href="https://ir.neximmune.com/static-files/4fa9b727-d4d2-4a06-8014-acf095926ddd">letter</a> dated June 21, NexImmune&rsquo;s leadership invited shareholders to meet earlier this morning. The special meeting was to be held virtually via a live webcast. Management took this course of action to help improve efficiency and also ensure greater participation. This last point is especially important for the company due to its prior struggles, which are listed below:



<ul><li>On Dec. 21, 2023, NexImmune initiated a special meeting to consider a corporate dissolution. However, it was adjourned due to a lack of quorum.</li>



<li>On Jan. 18, 2024, NexImmune reconvened the meeting. However, the matter was again adjourned due to lack of quorum.</li>



<li>Management scheduled a second adjournment for Feb. 7 but postponed it prior to its occurrence.</li>



<li>On Feb. 2, the biotech firm announced that it would sell shares and warrants of NEXI stock for approximately $3.67 million.</li>



<li>The company made other efforts to secure much-needed financing, but they were unsuccessful.</li>
</ul>Ultimately, the board of NexImmune felt that dissolution was the best decision in an unfortunate circumstance.



<h2>NEXI Stock Pops Higher on Hopes of an Orderly Exit</h2>



One critical factor to consider regarding NEXI stock is that the majority of its shareholders consistently voted for dissolution. However, because the quorum &mdash; or the minimum number of shareholders needed to be present &mdash; was never met, an ultimate resolution could not be achieved. It&rsquo;s possible, then, that today&rsquo;s dramatic lift may signal such a resolution.



Either way, the fundamental reason for bullishness in NEXI centers on the implied orderly exit. It&rsquo;s clear that many participating shareholders want to dissolve the entity. The reason is that, per management, one of the few other alternatives is to declare bankruptcy, which could be a messy situation. Most importantly, common stock shareholders would be <a href="https://www.investopedia.com/ask/answers/10/stock-holder-lose-equity-chapter-11.asp#:~:text=Common%20stock%20shareholders%20are%20last,dollar%2C%20if%20anything%20at%20all.">last in line</a> to recover any assets following a liquidation.



The advantage of a dissolution or even a gradual winding down of the business is <a href="https://www.cfo.com/news/bankruptcy-vs-winding-down-for-troubled-companies-chapter-11-chapter7-David-Dragich/689850/">management&rsquo;s control of the process</a>. In NexImmune&rsquo;s case, it could cease operations under its own terms, settle with creditors and then distribute any available assets to shareholders.



Finally, a dissolution is preferable over a bankruptcy when it comes to reputation. Bankruptcies are public and carry a stigma that&rsquo;s difficult to shake. However, a dissolution is more discrete and can potentially better preserve business and investor relationships for any future endeavors.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/what-is-going-on-with-neximmune-nexi-stock-today/">What Is Going on With NexImmune (NEXI) Stock Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

What Is Going on With NexImmune (NEXI) Stock Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NexImmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/nexi-stock-quote/">NEXI</a>) stock is no longer trading on the Nasdaq Exchange after the company&rsquo;s shares <a href="https://ir.neximmune.com/static-files/3a32ec62-57db-4193-b40b-f2c88363cda4">were delisted on Friday morning</a>.



This saw shares of NEXI stock removed from the Nasdaq Exchange when markets opened this morning. This came after several warnings from the Listing Qualifications Department that a delisting was comping.



The Listing Qualifications Department decided to delist shares of NEXI stock as it identified NexImmune as a public shell company. NexImmune appealed this decision late last year but couldn&rsquo;t change the listing hearings panel&rsquo;s mind.



<h2>What&rsquo;s Next for NEXI Stock?</h2>



There doesn&rsquo;t appear to be any future for NexImmune as the company is already considering how best to liquidate its assets. It held a meeting for this on Thursday but didn&rsquo;t reach a conclusion.



NexImmune is going to give it another try with an additional meeting on July 19. Stockholders on record as of June 11 will be eligible to take part in the shareholder meeting determining the company&rsquo;s future.



It&rsquo;s also unclear what will happen to NEXI stock now. The company hasn&rsquo;t said anything about listing its shares on another exchange following the Nasdaq delisting.



Investors on the lookout for more of the most recent stock market stories today are going to want to stick around!



We have all of the hottest stock market news that traders need to know about on Friday! A few examples include what&rsquo;s happening with shares of Vicinity Motor&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vev-stock-quote/">VEV</a>), AT&amp;T&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/t-stock-quote/">T</a>) and Plug Power&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/plug-stock-quote/">PLUG</a>) stock today. You can catch up on all of this news at the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-vicinity-motor-vev-stock-up-114-today/">Why Is Vicinity Motor (VEV) Stock Up 114% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/att-data-breach-were-you-affected/">AT&amp;T Data Breach: Were You Affected?</a></li>



<li><a href="https://investorplace.com/2024/07/investors-are-counting-on-jerome-powell-to-save-plug-power-plug-stock/">Investors Are Counting on Jerome Powell to Save Plug Power (PLUG) Stock</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/nexi-stock-alert-neximmune-delists-from-nasdaq/">NEXI Stock Alert: NexImmune Delists From Nasdaq</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NEXI Stock Alert: NexImmune Delists From Nasdaq

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Qualigen (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) stock is rocketing higher on Friday after the clinical-stage therapeutics company <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1460702/000149315224027015/form8-k.htm">secured a new loan</a>.



Qualigen reached an agreement with an investor for a $2 million Senior Note due July 8, 2025 with an 18% annual interest rate. This note grants the company an extra $2 million of cash to work with.



There are some stipulations that come with this new investor loan. That includes changes to the Qualigen board of directors. This has Richard David, Sidney Emery, Kurt Kruger and Ira Ritter each resigning for this board seats.



Following that, the board of directors appointed three new members to replace the outing ones. They are Campbell Becher, Robert Lim and Cody Price. The roles of these board members haven&rsquo;t been determined yet.



<h2>QLGN Stock Reactions Today</h2>



Following these changes, QLGN stock is seeing major activity on Friday. This has about 297 million shares have changed hands as of this writing. That&rsquo;s well above its daily average trading volume of about 5.6 million shares.



QLGN stock is up 141.2% as of Friday morning.



Investors will find more of the most recent stock market stories below!



We offer up all of the hottest stock market news available on Friday! That includes everything happening with shares of NexImmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nexi-stock-quote/">NEXI</a>) stock, Vicinity Motor&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vev-stock-quote/">VEV</a>) stock and AT&amp;T&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/t-stock-quote/">T</a>)&nbsp;stock today. You can read up on all of these matters at the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/07/nexi-stock-alert-neximmune-delists-from-nasdaq/">NEXI Stock Alert: NexImmune Delists From Nasdaq</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-vicinity-motor-vev-stock-up-114-today/">Why Is Vicinity Motor (VEV) Stock Up 114% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/att-data-breach-were-you-affected/">AT&amp;T Data Breach: Were You Affected?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-qualigen-qlgn-stock-up-141-today/">Why Is Qualigen (QLGN) Stock Up 141% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Qualigen (QLGN) Stock Up 141% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) stock is rallying higher on Friday after the electric vehicle (EV) company <a href="https://finance.yahoo.com/news/zapp-ev-secures-increased-commitment-103000365.html">secured a commitment for up to $50 million</a>.



This is an update to a standby equity purchase agreement that was signed in February 2024 for $10 million. With this change, the company now has access to up to $50 million. That replaces the original $10 million agreement.



Zapp Electric Vehicles notes that this money will come from it selling shares of ZAPP stock to an affiliate of Yorkville Advisors Global, LP. Additionally, the lender has agreed to advance $4 million to the company through three tranches tied to the standby equity purchase agreement.



Zapp Electric Vehicles founder and CEO Swin Chatsuwan said the following about the funding.




&ldquo;This increased investor support provides the financial resources to accelerate the development of our business while retaining significant discretion as to the timing and amount of share issuances by Zapp, as needed. With our asset-light business model and modest funding requirements compared to other sectors, Zapp aims to deploy capital as efficiently as possible to maximize value for shareholders and launch sales of the i300 in an expanding set of countries.&rdquo;




<h2>ZAPP Stock Movement Today</h2>



With all of this news comes increased interest and heavy trading of ZAPP shares. That has more than 14 million units changing hands as of this writing. This is well above its daily average trading volume of about 7.4 million shares.



ZAPP stock is up 30.5% as of Friday morning.



Investors will want to stick around for even more of the most recent stock market stories!



We have all of the hottest market happenings investors need to know about on Friday! Among that is what&rsquo;s going on with shares of Rivian&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>), Qualigen&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) and NexImmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nexi-stock-quote/">NEXI</a>) stock today. All of that news is ready at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/mizuho-just-raised-its-price-target-on-rivian-rivn-stock/">Mizuho Just Raised Its Price Target on Rivian (RIVN) Stock</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-qualigen-qlgn-stock-up-141-today/">Why Is Qualigen (QLGN) Stock Up 141% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/nexi-stock-alert-neximmune-delists-from-nasdaq/">NEXI Stock Alert: NexImmune Delists From Nasdaq</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-zapp-electric-vehicles-zapp-stock-up-31-today/">Why Is Zapp Electric Vehicles (ZAPP) Stock Up 31% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Zapp Electric Vehicles (ZAPP) Stock Up 31% Today?

NexImmune (NEXI) has issued an update. NexImmune, Inc. is set to dissolve following stockholder approval, leading to the resignation of all board m...

NexImmune Dissolution Progresses with New Sole President

ACOR

BTTR

CADL

CZOO

DOGZ

EFSH

GCTS

HUBC

IMCC

MDIA

NEXI

NRSN

PLUG

QLGN

RIVN

ZAPP

Small Cap

Opinion

Press Releases

Thinking about buying stock in Neximmune, ShiftPixy, Ampio Pharmaceuticals, Seelos Therapeutics, or Nio Inc?

Thinking about buying stock in Johnson & Johnson, Fortress Biotech, MicroStrategy, Neximmune, or ShiftPixy?

Thinking about buying stock in Dyne Therapeutics, Applied Therapeutics, ON Semiconductor, Mereo BioPharma, or Neximmune?

Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Financing

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Comments

NexImmune

Notizie

Ultime notizie per NexImmune (OTC:NEXI) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO